GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity

Ähnliche Einträge

• Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
  von: Renata Spezani, et al.
  Veröffentlicht: (2025)
• Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
  von: Liang Zheng, et al.
  Veröffentlicht: (2025)
• Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
  von: Suleiman Al Ashi, et al.
  Veröffentlicht: (2025)
• Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
  von: Huilin Tang, et al.
  Veröffentlicht: (2025)
• Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
  von: Flora Lambert, et al.
  Veröffentlicht: (2025)